Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: thrombosis therapy - APT Therapeutics

Drug Profile

Research programme: thrombosis therapy - APT Therapeutics

Alternative Names: APT 102; APT 301; APT 302; APT 502

Latest Information Update: 28 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator APT Therapeutics
  • Developer APT Therapeutics; Washington University School of Medicine
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Platelet activating factor inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Myocardial infarction; Stroke

Highest Development Phases

  • No development reported Cancer metastases; Stroke; Thrombosis

Most Recent Events

  • 28 Nov 2018 No recent reports of development identified for preclinical development in Stroke in USA (IV, Injection)
  • 28 Nov 2018 No recent reports of development identified for preclinical development in Thrombosis in USA (IV, Injection)
  • 03 Jan 2017 APT Therapeutics and AstraZeneca enter research and option collaboration for development of APT 102
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top